NuVasive Nabs Nucleus Replacement Device With $43.5 Mil. Pearsalls’ Buy

NuVasive expects its cervical nucleus-replacement device to be the first of its kind on the U.S. market in 2010, following its $43.5 mil. purchase of Pearsalls' intellectual property portfolio